Name | N2-(4-Fluorophenyl)-N4-phenyl-N6-(2-pyrimidinylmethyl)-1,3,5-triazine-2,4,6-triamine |
---|---|
Synonyms |
1,3,5-Triazine-2,4,6-triamine, N2-(4-fluorophenyl)-N4-phenyl-N6-(2-pyrimidinylmethyl)-
N2-(4-Fluorophenyl)-N4-phenyl-N6-(2-pyrimidinylmethyl)-1,3,5-triazine-2,4,6-triamine |
Description | ASP 2905 (ASP2905) is a novel potent, selective, orally bioavailable inhibitor of voltage-gated potassium channel KCNH3 with IC50 of 9.0 nM; displays minimally bound with low affinities to 55 transmembrane proteins; decreases the frequency of spontaneous inhibitory postsynaptic currents in cultured rat hippocampal neurons at 0.1-1 uM; reverses the disruption of spontaneous alternation behavior induced by MK-801 and scopolamine in mice, and ameliorates the cognitive deficits of aged rats. Alzheimer Disease Phase 1 Discontinued |
---|---|
References | References 1. Takahashi S, et al. Eur J Pharmacol. 2017 Sep 5;810:26-35. View Related Products by Target Potassium Channel Alzheimer Disease |
Density | 1.4±0.1 g/cm3 |
---|---|
Boiling Point | 600.5±65.0 °C at 760 mmHg |
Molecular Formula | C20H17FN8 |
Molecular Weight | 388.401 |
Flash Point | 317.0±34.3 °C |
Exact Mass | 388.156006 |
LogP | 2.26 |
Vapour Pressure | 0.0±1.7 mmHg at 25°C |
Index of Refraction | 1.739 |